Nurix Therapeutics (NRIX) said Wednesday it received PRIME designation from the European Medicines Agency for NX-5948 to treat adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The PRIME, or priority medicines, designation follows "encouraging" safety and efficacy data from an ongoing phase 1 trial, the company said.

To be eligible for PRIME, medicines must target an unmet medical need and show potential benefit for patients based on early clinical data, the firm said.